Showing 2 posts of 2 posts found.

Takeda building

Takeda agree $856m deal with Ovid to take over soticlestat development

March 4, 2021
Ovid, Takeda, epilepsy treatment, epiplepsy, soticlestat

Ovid Therapeutics and Takeda have agreed a deal worth up to $856 million, allowing the latter to take over development …


Ovid’s Angelman syndrome therapy falls short at Phase 3

December 2, 2020
Research and Development Angelman syndrome, Ovid

Ovid Therapeutics has revealed disappointing results for its therapy OV101 (gaboxadol) in the treatment of Angelman syndrome, admitting that it failed …

Latest content